Investors Watch List: USD Partners LP (NYSE:USDP), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), Trinity Industries Inc. (NYSE:TRN), CommScope Holding Company, Inc.

USD Partners LP (NYSE:USDP) plans to report fourth quarter 2015 financial and operating results after market close on Wednesday, March 9, 2016. The Partnership will host a conference call and webcast regarding fourth quarter 2015 results at 11:00 a.m. Eastern Time (10:00 a.m. Central Time) on Thursday, March 10, 2016.

USD Partners LP (NYSE:USDP) belongs to Services sector. Its net profit margin is 14.70% and weekly performance is -5.18%. On last trading day company shares ended up at $6.04. USD Partners LP (NYSE:USDP) distance from 50-day simple moving average (SMA50) is -5.48%.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced that it will report its financial results for the year ended December 31, 2015, on Tuesday, March 1, 2016, before the U.S. financial markets open.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares fell -1.21% in last trading session and ended the day at $13.02. CNCE return on assets is 11.50%. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) quarterly performance is -43.27%.

On 18 February, Trinity Industries Inc. (NYSE:TRN) announced earnings results for the fourth quarter ended December 31, 2015. Record operating margin for the Rail Group of 23.6% with record deliveries of 8,835 railcars

On 24 February, Trinity Industries Inc. (NYSE:TRN) shares fell -0.57% and was closed at $15.64. TRN EPS growth in last 5 year was 45.90%. Trinity Industries Inc. (NYSE:TRN) year to date (YTD) performance is -34.54%.

CommScope Holding Company, Inc. (NASDAQ:COMM) ended the last trading day at $25.22. Company weekly volatility is calculated as 5.21% and price to cash ratio as 7.75. CommScope Holding Company, Inc. (NASDAQ:COMM) showed a weekly performance of 9.22%.

Esperion Therapeutics Inc (NASDAQ:ESPR) had its price objective cut by stock analysts at Barclays from $76.00 to $28.00 in a research report issued on Wednesday,StockTargetPrices.com reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays’ price objective points to a potential upside of 77.89% from the company’s current price.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares advanced 2.22% in last trading session and ended the day at $16.09. ESPR return on assets is -16.90%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) quarterly performance is -38.66%.

Leave a Reply

Your email address will not be published. Required fields are marked *